Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1371390 | 0.85 | TAAR1 (0.57) | TAAR1CA2CA1CA9CA12 | |
| SCHEMBL23703162 | 0.81 | TAAR1 (0.53) | TAAR1IDO1AGXTEGFRERBB2 | |
| SCHEMBL4871516 | 0.81 | TAAR1 (0.53) | TAAR1CA2CA1CA9CA12 | |
| SCHEMBL1118907 | 0.81 | CA1 (0.57) | TAAR1CA2CA1CA9CA12 | |
| SCHEMBL1641618 | 0.79 | RECQL (0.58) | CA2CA1CA9CA12RECQL | |
| SCHEMBL23733099 | 0.79 | TAAR1 (0.50) | TAAR1IDO1AGXTBACE1EGFR | |
| SCHEMBL7659779 | 0.78 | TAAR1 (0.58) | TAAR1CA2IDO1RECQL | |
| SCHEMBL4878820 | 0.78 | TAAR1 (0.58) | TAAR1IDO1AGXTRECQLBACE1 | |
| SCHEMBL4881416 | 0.78 | TAAR1 (0.58) | TAAR1CA2CA1CA12IDO1 | |
| SCHEMBL23732878 | 0.77 | TAAR1 (0.57) | TAAR1CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| CN-115916966-A | STRAD binding agents and uses thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| EP-4097223-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155004-A1 | STRAD-BINDING AGENTS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-08-05 | — | — | WO | disclosed |
| CN-107922362-A | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2018-04-17 | — | — | CN | disclosed |
| EP-2683703-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2014-01-15 | — | — | EP | disclosed |
| WO-2012120057-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | TAAR1 4465/4885CA2 2899/4885CA1 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.